New drug combo aims to shrink hard-to-treat cancers
NCT ID NCT07123415
First seen Nov 19, 2025 · Last updated May 22, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug called APX-343A, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 110 adults with advanced cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gangnam Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, South Korea
Contact
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.